Aerpio raises $27m to take novel diabetic macular oedema candidate through Ph II
This article was originally published in Scrip
Executive Summary
Aerpio Therapeutics, based in Cincinnati, Ohio in the US, has raised $27 million in a Series A financing round to fund the first-in-class Tie2 receptor activator AKB-9778 through 2014, when the company plans to complete a Phase II clinical trial in the treatment of diabetic macular oedema (DMO).